Skip to main content

Table 2 Comparison of the epidemiological characteristics for patients received crizotinib treatment

From: Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Characteristics Group P value
Total 1-CRZ 1-PP N1-PP  
Total, n 65 31 22 12  
Gender, n (%)
 Male 31 (47.7) 18 (58.1) 8 (36.4) 5 (41.7) 0.267
 Female 34 (52.3) 13 (41.9) 14 (63.6) 7 (58.3)  
Median age, year (range) 50.2 (23–73) 50.9 (30–73) 51.9 (23–71) 42.5 (23–61) 0.640
Smoking, n (%)
Never 44 (67.7) 19 (61.3) 17 (77.3) 8 (66.7) 0.470
Current/Former 21 (32.3) 12 (38.7) 5 (22.7) 4 (33.3)  
ECOG score, n (%)
0 or 1 55 (84.6) 29 (93.5) 18 (81.8) 8 (66.7) 0.035
> = 2 10 (15.4) 2 (6.5) 4 (18.2) 4 (33.3)  
Extent of disease, n (%)
Locally advanced 10 (15.4) 5 (16.1) 3 (13.6) 2 (16.7) 0.961
Metastatic 55 (84.6) 26 (83.9) 19 (86.4) 10 (83.3)  
  1. Note. — Unless otherwise indicated, the data are shown as numbers with percentages in parentheses. The statistical analysis for age was performed using the Mann–Whitney test. The statistical analyses for other clinical features were performed using the Chi-Square test